KR20180043834A - 세포 신장 방법들 및 치료 조성물들 - Google Patents

세포 신장 방법들 및 치료 조성물들 Download PDF

Info

Publication number
KR20180043834A
KR20180043834A KR1020187009130A KR20187009130A KR20180043834A KR 20180043834 A KR20180043834 A KR 20180043834A KR 1020187009130 A KR1020187009130 A KR 1020187009130A KR 20187009130 A KR20187009130 A KR 20187009130A KR 20180043834 A KR20180043834 A KR 20180043834A
Authority
KR
South Korea
Prior art keywords
mscs
cells
medium
cultured
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187009130A
Other languages
English (en)
Korean (ko)
Inventor
바랄카 바네르제에
샤르로테 모르간
그라함 베세이
니콜레 한나흐 패커
Original Assignee
셀 아이디어스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903658A external-priority patent/AU2015903658A0/en
Application filed by 셀 아이디어스 피티와이 엘티디 filed Critical 셀 아이디어스 피티와이 엘티디
Publication of KR20180043834A publication Critical patent/KR20180043834A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187009130A 2015-09-08 2016-09-08 세포 신장 방법들 및 치료 조성물들 Ceased KR20180043834A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903658 2015-09-08
AU2015903658A AU2015903658A0 (en) 2015-09-08 Cell expansion methods and therapeutic compositions
PCT/AU2016/000316 WO2017041133A1 (en) 2015-09-08 2016-09-08 Cell expansion methods and therapeutic compositions

Publications (1)

Publication Number Publication Date
KR20180043834A true KR20180043834A (ko) 2018-04-30

Family

ID=58240422

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009130A Ceased KR20180043834A (ko) 2015-09-08 2016-09-08 세포 신장 방법들 및 치료 조성물들

Country Status (10)

Country Link
US (2) US20180236003A1 (https=)
EP (1) EP3347449A4 (https=)
JP (3) JP6995752B2 (https=)
KR (1) KR20180043834A (https=)
CN (1) CN108348555B (https=)
AU (1) AU2016321448B2 (https=)
CA (1) CA3035931A1 (https=)
HK (1) HK1252778A1 (https=)
TW (1) TWI760313B (https=)
WO (1) WO2017041133A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531269A (ja) * 2015-10-23 2018-10-25 リグスホスピタレットＲｉｇｓｈｏｓｐｉｔａｌｅｔ 脂肪由来幹細胞に基づく幹細胞治療
WO2018213795A1 (en) * 2017-05-18 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
MA52883A (fr) 2018-06-15 2021-05-26 Prieto Manuel Hermida Composition pharmaceutique pour dermatologie et ses utilisations
CN109022360A (zh) * 2018-07-03 2018-12-18 湖南未名三胞转化医学科技有限公司 自体脂肪干细胞共培养促进外周血造血干细胞增殖方法
CN110106142B (zh) * 2019-05-30 2020-05-12 深圳阿尔法生物科技有限公司 一种制备“百亿”级脂肪源再生细胞的生产工艺
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
KR102193175B1 (ko) 2020-04-07 2020-12-18 주식회사 엑소스템텍 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores
US20230365937A1 (en) * 2020-10-26 2023-11-16 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
WO2022192429A1 (en) * 2021-03-10 2022-09-15 Terasaki Insutitute For Biomedical Innovation Constructs comprising fibrin or other blood products for meat cultivation and other applications
BR102022016233A2 (pt) * 2022-08-16 2024-02-27 Omics Biotecnologia Animal Ltda Concentrado de proteínas e peptídeos derivados de células estromais mesenquimais, método de obtenção e uso de concentrado

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404656D0 (en) * 2004-03-02 2004-04-07 Univ Manchester Treatment of spinal conditions
WO2008034803A1 (en) * 2006-09-18 2008-03-27 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
WO2012030968A1 (en) * 2010-08-31 2012-03-08 Renovocyte, LLC Systemic, allogenic stem cell therapies for treatment of diseases in animals
DK2744892T3 (en) 2011-09-23 2019-04-23 Cell Ideas Pty Ltd THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS
US20140219972A1 (en) 2013-02-05 2014-08-07 The Board Of Trustees Of The Leland Stanford Junior University Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
EP3405204B1 (en) * 2016-08-26 2025-06-25 Restem Llc Composition and methods of using umbilical cord lining stem cells

Also Published As

Publication number Publication date
CA3035931A1 (en) 2017-03-16
US20180236003A1 (en) 2018-08-23
WO2017041133A1 (en) 2017-03-16
AU2016321448B2 (en) 2023-02-02
EP3347449A4 (en) 2019-03-20
TW201720922A (zh) 2017-06-16
TWI760313B (zh) 2022-04-11
JP6995752B2 (ja) 2022-02-04
US20210260129A1 (en) 2021-08-26
CN108348555A (zh) 2018-07-31
JP2022186992A (ja) 2022-12-15
JP2022027928A (ja) 2022-02-14
EP3347449A1 (en) 2018-07-18
CN108348555B (zh) 2022-07-08
AU2016321448A1 (en) 2018-03-15
HK1252778A1 (zh) 2019-05-31
JP2018526447A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
KR20180043834A (ko) 세포 신장 방법들 및 치료 조성물들
Galderisi et al. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years?
da Fonseca et al. Human platelet lysate–A potent (and overlooked) orthobiologic
US20180243376A1 (en) Methods and non-immunogenic compositions for treating inflammatory disorders
Pereira et al. Effects of human mesenchymal stem cells isolated from Wharton’s jelly of the umbilical cord and conditioned media on skeletal muscle regeneration using a myectomy model
T Harris Umbilical cord tissue mesenchymal stem cells: characterization and clinical applications
Rosochowicz et al. Conditioned medium–is it an undervalued lab waste with the potential for osteoarthritis management?
KR20190128622A (ko) 주산기 조직 유래된 중간엽 줄기 세포: 그의 제조 방법 및 용도
AU2019348047B2 (en) Mesenchymal stem cells and products therefrom
JP2010529987A5 (https=)
KR20100035648A (ko) 체외 배양 및 증식 자기재생성 집락 형성 세포를 이용한 질환 및 장애 치료방법
WO2014053418A2 (en) Method for obtaining mesenchymal stem cells and use thereof
US20240393285A1 (en) Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells
Da Silva et al. The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives
WO2011036632A1 (en) Composition comprising a haematic component and its use for the treatment of degenerative joint disease
CN114341346B (zh) 用于治疗骨关节炎的治疗性凋亡细胞
JP6250706B2 (ja) 変形性関節症の予防または治療における異系間質血管層細胞および異系間葉前駆細胞の使用
CN108126187A (zh) 一种组合物和其制备方法
Bi et al. Injectable Photo-cross-linkable Porous Composite Hydrogels with Exosomes for M2 Macrophage Polarization and Cartilage Defect regeneration
CN121203952A (zh) 培养间充质干细胞的组合物、方法、间充质干细胞及其应用
Mehling et al. Evaluation of Immune response to Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation
WO2022256865A1 (en) Use of mesenchymal stem cells and products thereof
Cormier et al. Office-Based Orthobiologic Procedures for Tendons
Delecave Dias Effects Of Cell-Free Conditioned Media on Healing of Rat Achilles Tendon
KR20260020331A (ko) 인간 태반 유래 중간엽줄기세포에서 추출된 유전체 dna 절편 및 태반성장인자를 포함하는 상처 치료 또는 조직 재생용 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180330

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210908

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231129

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240202

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231129

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I